Is intra-arterial delivery superior to intravenous delivery of autologous bone marrow mononuclear cells in acute ischemic stroke?
At low and high doses of MNCs, we found that IV or IA achieves similar structural and functional outcomes after stroke.
DCs pulsed with an IL-2 gene-encoded vaccinia virus tumor oncolysate (DC-IL-2VCO) produced safe and effective immune responses in a murine CC-36 colon adenocarcinoma model. This vaccine (DC-MelVac; Patent no. 11221/5) has the potential to treat humans with cancer, and has received FDA approval for use in Phase I clinical trials.